Eli Lilly Approved Obesity Drug for Mystery 79-Year-Old Patient

The approval of Eli Lilly’s obesity drug retatrutide for a 79-year-old mystery patient under the FDA’s compassionate use program has sparked significant interest and scrutiny. This move highlights the FDA’s efforts to expedite access to potentially life-saving experimental treatments for severe medical conditions, though it raises questions about equitable access and the transparency of such programs. As millions await official approval and broader access, this case underscores the ongoing debate about the balance between innovation and patient rights in drug development and distribution.